Titan Biotech Ltd

Titan Biotech Limited will hold its Thirty-Fourth Annual General Meeting on September 29, 2026, at 3:00 p.m. (IST) via video conferencing, with the Register of Members closed from September 23, 2026, to September 29, 2026, and a record date set for September 22, 2026, to determine eligibility for the final dividend for the financial year ended March 31, 2026. E-voting will be available from September 26, 2026, at 10:00 a.m. (IST) to September 28, 2026, at 5:00 p.m. (IST), with September 22, 2026, as the cut-off date.

Titan Biotech Limited announced several key decisions following a board meeting, informing the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The company will issue bonus shares in a ratio of 1:4, requiring Rs 2,06,59,250 and with an estimated credit/dispatch date of November 3, 2026. Simultaneously, the authorized share capital will increase from Rs 10,00,00,000 to Rs 10,40,00,000, expanding the company’s capacity to issue shares. Additionally, the board re-appointed Mr. Rohit Jain as an Independent Director for a five-year term, from September 30, 2026, to September 29, 2031. Mr. Jain, a Partner at Singhania & Co. LLP, brings extensive legal and corporate experience to the role.

Titan Biotech Limited has fixed September 22, 2026, as the record date for determining entitlement of members to a final dividend of Rs 0.50 per equity share of Rs 2 each for the financial year ended March 31, 2026, following a recommendation by the board of directors on May 30, 2026.

Titan Biotech Limited will seek shareholder approval for a bonus share issue at a board meeting scheduled for Thursday, September 3, 2026, according to a regulatory filing with the BSE Ltd. on August 31, 2026. The company has also closed its trading window for designated persons from August 31, 2026, and it will remain closed for 48 hours after the outcome of the board meeting is declared.

Titan Biotech Limited will close its trading window for all designated persons, their immediate relatives, and connected persons from August 31, 2026, until 48 hours after the conclusion of a board meeting scheduled for September 3, 2026, to consider a proposal for the issue of bonus shares, according to a filing with the BSE Limited.

Titan Biotech Ltd share price softened by 0.54% to Rs 396.05. The Company's net profit surged by 44.21% to Rs 9.46 crore, while revenue from operations gained significantly 21.18% to Rs 59.17 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.11 lakh crore, climbing 14.40%. It has eased by 0.10% over last one week and advanced by 12.48% in last one month while the market capitalization of Titan Biotech Ltd has slipped by 1.65% and 12.55% in the same period respectively. Profit before tax (PBT) of Titan Biotech Ltd stood at Rs 12.73 crore in Q2 FY26, expanding by 56.97% year-on-year, and rallying 23.83% quarter-on-quarter. EBITDA came in at Rs 11 crore, jumping 33.17% YoY and surging by 40.53% sequentially. Total expenses advancing by 18.88% to Rs 48.05 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.93 crore, going up by 15.52% YoY, while employee benefits expense was at Rs 8.7 crore, contracting 7.84% YoY. For the TTM ended FY26, revenue from operations declined slightly by 4.64% to Rs 156.45 crore, while net profit plunged by 22.78% to Rs 18.27 crore, compared to previous TTM. EBITDA jumped by 3237% to Rs 21.52 crore, and PBT tanked by 22.71% to Rs 24.37 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 20.12 crore in FY26, as against Rs 21.15 crore in FY25. Titan Biotech Ltd rallied 353.30% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.

Titan Biotech Limited will hold a board meeting on Thursday, August 13, 2026, to consider and approve unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, according to a filing with the BSE Ltd. The trading window for designated persons of the company has been closed since Wednesday, July 1, 2026, and will remain closed until 48 hours after the outcome of the board meeting is declared.

Net profit of Titan Biotech rose 66.17% to Rs 6.73 crore in the quarter ended March 2026 as against Rs 4.05 crore during the previous quarter ended March 2025. Sales rose 38.84% to Rs 48.83 crore in the quarter ended March 2026 as against Rs 35.17 crore during the previous quarter ended March 2025. For the full year,net profit rose 38.83% to Rs 29.89 crore in the year ended March 2026 as against Rs 21.53 crore during the previous year ended March 2025. Sales rose 31.79% to Rs 206.19 crore in the year ended March 2026 as against Rs 156.45 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales48.8335.17 39 206.19156.45 32 OPM %19.8912.99 -18.7216.25 - PBDT11.585.87 97 43.1028.54 51 PBT10.285.03 104 38.1724.37 57 NP6.734.05 66 29.8921.53 39 Powered by Capital Market - Live

Titan Biotech announced that the Board of Directors of the Company at its meeting held on 30 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.

Titan Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2026.